Inhibrx Biosciences, Inc.
INBX$175M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaLA JOLLA156 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 12, 2026
7wMarket Overview
Stock performance and key metrics
INBX News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
INBRX-106
Head and Neck Squamous Cell Carcinoma (HNSCC)
INBRX-109
Conventional Chondrosarcoma
INBRX-106 - Hexavalent OX40 agonist antibody
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
INBRX-106 | Phase 3 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
INBRX-109 | Phase 2 | Conventional Chondrosarcoma | - | - |
INBRX-106 - Hexavalent OX40 agonist antibody | Phase 2 | Solid Tumor | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply